今天3分钟我们来聊聊从「终身吃药」到「一针治愈」——全球首个体内CRISPR疗法，离上市只差最后一步

本期科普全球首个进入上市审批的体内CRISPR疗法lonvo-z，讲解它一针治愈遗传性血管性水肿的原理、亮眼临床数据与当前审评进度，揭秘基因编辑技术从体外走向体内的里程碑意义。

参考文献：

1. Intellia Therapeutics. FDA Acceptance of BLA with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for HAE. 2026-09-08. GlobeNewsWire

2. HAELO Phase 3 Trial Results. New England Journal of Medicine, 2026.

3. Intellia Therapeutics. Q2 2026 Financial Results and Business Updates. 2026-08-06. Intellia IR

4. GeneTech Times. One CRISPR Dose, 87% Fewer Attacks: Inside Intellia's Phase 3 Win for HAE. 2026-10-02. 链接

5. HCPLive. Lonvo-z BLA Accepted by FDA With Priority Review for HAE. 2026-09-08. 链接